(Reuters) – Myovant Sciences Ltd said on Tuesday its combination therapy met the main goal of a late-stage study testing the treatment in women with uterine fibroids.
The company said 73.4% of women receiving the once-daily treatment showed a greater reduction in menstrual blood loss compared with 18.9% of women receiving placebo.
The treatment, consisting of Myovant’s Relugolix and hormone therapies estradiol and norethindrone acetate, also helped maintain bone mineral density at levels comparable to placebo over 24 weeks and was generally well tolerated.
Uterine fibroids are non-cancerous tumors that develop in or on the muscular walls of the uterus and are among the most common reproductive tract tumors, affecting about 5 million women in the United States.
There are currently limited treatment options for uterine fibroids, which cause heavy menstrual bleeding, heavy or painful periods, anemia and, in some cases, infertility.
Shares of the company rose 1.6% to $17.5 before the bell.
Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Shailesh Kuber